![Evaluation of Outcomes in Converting from Intravenous Ondansetron to Oral Granisetron: An Observational Study | Semantic Scholar Evaluation of Outcomes in Converting from Intravenous Ondansetron to Oral Granisetron: An Observational Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2d0f012ad6d0e3ae0dc8e69c5872abcccf48e245/2-Table1-1.png)
Evaluation of Outcomes in Converting from Intravenous Ondansetron to Oral Granisetron: An Observational Study | Semantic Scholar
![Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics | Drug Metabolism & Disposition Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics | Drug Metabolism & Disposition](https://dmd.aspetjournals.org/sites/default/files/highwire/dmd/47/3.cover-source.jpg)
Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics | Drug Metabolism & Disposition
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis
![Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience Mendonca S, Gupta D, Ali S, Gupta P - Saudi J Kidney Dis Transpl Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience Mendonca S, Gupta D, Ali S, Gupta P - Saudi J Kidney Dis Transpl](https://www.sjkdt.org/articles/2017/28/5/images/SaudiJKidneyDisTranspl_2017_28_5_1069_215147_t5.jpg)
Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience Mendonca S, Gupta D, Ali S, Gupta P - Saudi J Kidney Dis Transpl
![Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation | Pharmacogenomics Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation | Pharmacogenomics](https://www.futuremedicine.com/cms/10.2217/pgs.12.185/asset/images/medium/figure3.gif)
Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation | Pharmacogenomics
![These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE for injection, for intravenous useInitial U.S. Approval: 1959 These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE for injection, for intravenous useInitial U.S. Approval: 1959](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=image-03.jpg&id=605644)
These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE for injection, for intravenous useInitial U.S. Approval: 1959
View of Identification of Patients Eligible for IV-to-PO Conversion: A Cost-Minimization Study | Canadian Journal of Hospital Pharmacy
![Association of High-dose Cyclophosphamide, Cisplatin, and Carmustine Pharmacokinetics with Survival, Toxicity, and Dosing Weight in Patients with Primary Breast Cancer | Clinical Cancer Research Association of High-dose Cyclophosphamide, Cisplatin, and Carmustine Pharmacokinetics with Survival, Toxicity, and Dosing Weight in Patients with Primary Breast Cancer | Clinical Cancer Research](https://clincancerres.aacrjournals.org/content/clincanres/8/3/698/F1.large.jpg)